HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Clinical trial NCT06239532 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06239532
- Sponsor
- Qilu Hospital of Shandong University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2024-12-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.